Loading...
IDRSF
OTCM
Market cap1.15bUSD
Nov 20, Last price  
4.70USD
1D
0.00%
1Q
-35.17%
IPO
-73.89%
Name

Idorsia Ltd

Chart & performance

D1W1MN
OTCM:IDRSF chart
P/E
—
P/S
4.82
EPS
—
Vol. 1Y
186.09%
Shs. 5Y
8.50%
Rev. 5Y
25.23%
Div Yld LY
—
Div Yld TTM
—
Revenues
221m
+96.43%
0158,085,00060,618,00023,819,00071,758,00035,349,00097,102,000152,386,000112,508,000221,000,000
Net income
-112m
L-57.54%
-335,143,000-14,269,000-386,390,000-494,649,000-445,119,000-634,595,000-827,896,000-297,921,000-263,757,000-112,000,000
CFO
-153m
L-58.61%
-263,338,00095,495,000-352,817,000-462,039,000-364,667,000-589,895,000-859,108,000-629,296,000-370,232,000-153,227,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Related entities

Subsidiaries (3)
Idorsia Investments SARL
Idorsia Pharmaceuticals Ltd
IDORSIA PHARMACEUTICALS SPAIN SL

Key people

Jean-Paul Clozel
Chairman of the Board · since 2024
Chief Executive Officer, Chief Financial Officer, Member of the Executive Board · since 2024
Vice Chairman of the Board, Lead Independent Director · since 2024
Julien Gander
Executive Vice President, Chief Legal & Corporate Development Officer, Member of the Executive Board · since 2025
Arno Groenewoud
Chief Financial Officer, Executive Vice President, Member of the Executive Board · since 2024
Martine Clozel
Executive Vice President, Chief Scientific Officer, Member of the Executive Board · since 2017
Alberto Gimona
Executive Vice President, Head of Global Clinical Development, Member of the Executive Board · since 2022
Non-Executive Director · since 2024
Srishti Gupta
Non-Executive Independent Director · since 2021
Non-Executive Independent Director · since 2023
Sandesh Mahatme
Non-Executive Independent Director · since 2020
IPO date
Jun 16, 2017
Employees
636
Domiciled in
CH
Incorporated in
CH
Headquarters & legal address
Hegenheimermattweg 91
Allschwil, BL 4123
CH
Other language
Idorsia AG

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT